Search
Business Practice
Business
Development
Legal
Policy
Practice
Regulatory
News
Media
All Videos
Insights
Interviews
Peer Exchange
Podcasts
Clinical
Dermatology
Endocrinology
Gastroenterology
Legal
Neurology
Oncology
Ophthalmology
Rare Disease
Rheumatology
Conferences
Conference Coverage
Conference Listing
Resources
Authors
Biosimilar Resources
Continuing Education
Polls
Subscribe
Search
Business Practice
See All >
Business
Development
Legal
Policy
Practice
Regulatory
Stakeholders Summit: Provider Education on Biosimilars
Pfizer's Citizen Petition on Biosimilar Communications
Combating Misinformation and Misconceptions About Biosimilars
Targeted Education for Biosimilar Stakeholders
US Versus EU Education on Biosimilars
The FDA's Approach to Biosimilar Education
Biosimilarity, Manufacturing Changes, and Comparability
Clinicians' Understanding of Manufacturing Changes
The Extrapolation of Indications
Selecting the Most Sensitive Population for Confirmatory Trials
Immunogenicity and Biosimilars
Misconceptions About Interchangeability
Clinical Studies for Biosimilars
The Future of US Biosimilars
The Role of Biosimilars in the US Healthcare System
Allowing the US Biosimilars Market to Flourish
Madelaine Feldman, MD: Prescribers' Understanding of Biosimilars
Molly Billstein Leber, PharmD, BCPS, FASHP: Dispelling Misconceptions About Biosimilar Approval and Use
Madelaine Feldman, MD: Physicians' Concerns Regarding Biosimilars
Molly Billstein Leber, PharmD, BCPS, FASHP: Pharmacists' Awareness of Biosimilars
Madelaine Feldman, MD: Practical Considerations for Biosimilars
Molly Billstein Leber, PharmD, BCPS, FASHP: Adoption of and Education on Biosimilars
Molly Billstein Leber, PharmD, BCPS, FASHP: Interchangeability Laws, Substitution, and the Future Role of Biosimilars
Next >>
x